Top Markets
Coin of the day
Pell Bio-Med Technology Co., Ltd. Pell Bio-Med Technology Co., Ltd.

Pell Bio-Med Technology Co., Ltd.

6949
Rangering i aksjer #4985
Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in... Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.
Aksjekurs
$47.38
Sist synkronisert: 2026-08-26
Markedsverdi
$3.11B
Endring (1 dag)
9.96%
Endring (1 år)
238.59%
Land
TW
Handel Pell Bio-Med Technology Co., Ltd. (6949)

Kategori

P/S-forhold for Pell Bio-Med Technology Co., Ltd. (6949)
P/S-forhold per 2026 TTM: 0
Ifølge Pell Bio-Med Technology Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Pell Bio-Med Technology Co., Ltd. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH